无驱动基因突变晚期非小细胞肺癌的免疫治疗进展

熊荣 生
广西壮族自治区南溪山医院胸外科 广西 541002

参考

[1].Oshim a Y, Tanim oto T, Yuji K, Tojo A. EGFR-TKI-Associated

Interstitial Pneum onitis in Nivolum ab-Treated Patients W ith Non-Sm all

Cell Lung Cancer[J]. JAM A Oncol 2018,4(8):1112-1115.

[2].Gandhi L, Rodr í guez-Abreu D, Gadgeel S, et al.

Pem brolizum ab plus Chem otherapy in M etastatic Non-Sm all-Cell Lung

Cancer[J]. N Engl J M ed 2018, 378(22):2078-2092.

[3].Paz-Ares L, Luft A, Vicente D, et al. Pem brolizum ab plus

Chem otherapy for Squam ous Non-Sm all-Cell Lung Cancer[J]. N Engl J

M ed 2018,379(22):2040-2051.

[4].M ok TSK, W u YL, Kudaba I, et al. Pem brolizum ab versus

chem otherapy for previously untreated, PD-L1-expressing, locally

advanced or m etastatic non-sm all-cell lung cancer (KEYNOTE-042): a

random ised, open-label, controlled, phase 3 trial[J]. Lancet

2019,393(5):1819-1830.

[5].Reck M , Rodr í guez-Abreu D, Robinson AG, et al.

Pem brolizum ab versus Chem otherapy for PD-L1-Positive

Non-Sm all-Cell Lung Cancer[J]. N Engl J M ed

2016,375(11):1823-1833.

[6].Brahm er J, Reckam p KL, Baas P, et al. Nivolum ab versus

Docetaxel in Advanced Squam ous-Cell Non-Sm all-Cell Lung Cancer[J].

N Engl J M ed 2015; 373(2):123-135.

[7].H orn L, Spigel DR, Vokes EE, et al. Nivolum ab Versus

Docetaxel in Previously Treated Patients W ith Advanced

Non-Sm all-Cell Lung Cancer: Two-Year Outcom es From Two

Random ized, Open-Label, Phase III Trials (CheckM ate 017 and

CheckM ate 057)[J]. Clin Oncol 2017,35(35):3924-1933.

[8].Rittm eyer A, Barlesi F, W aterkam p D, et al. Atezolizum ab versus

docetaxel in patients with previously treated non-sm all-cell lung cancer

(OAK): a phase 3, open-label, m ulticentre random ised controlled trial[J].

Lancet 2017,389(1):255-265.

[9].Fehrenbacher L, von Pawel J, Park K, et al. Updated Efficacy

Analysis Including Secondary Population Results for OAK: A

Random ized Phase III Study of Atezolizum ab versus Docetaxel in

Patients with Previously Treated Advanced Non-Sm all Cell Lung

Cancer[J].Thorac Oncol 2018,13(8):1156-1170.

[10].H erbst RS, Baas P, Kim DW , et al. Pem brolizum ab versus

docetaxel for previously treated, PD-L1-positive, advanced

non-sm all-cell lung cancer (KEYNOTE-010): a random ised controlled

trial[J]. Lancet 2016, 387(10027):1540-1550.

[11].Spigel DR, H ussein M A, M cLeod M , et al. Random ized results

of fixed-duration (1-yr) vs continuous nivolum ab in patients (pts) with

advanced non-sm all cell lung cancer (NSCLC)[J] .Ann Oncol 2017;

28(supp1-5).

[12].Kim DW , H erbst RS, Garon EB, et al. Long-term survival in

patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall

and in pts who com pleted 2 years of pem brolizum ab (pem bro)[J]. Ann

Oncol 2018; 29(supp1-8).

[13].Gettinger SN, W urtz A, Goldberg SB, et al. Clinical Features

and M anagem ent of Acquired Resistance to PD-1 Axis Inhibitors in 26

Patients W ith Advanced Non-Sm all Cell Lung Cancer[J]. Thorac Oncol

2018,13(6):831-839.